Lipocine Inc. (NASDAQ:LPCN – Get Free Report) was the recipient of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 278,400 shares, an increase of 155.6% from the March 31st total of 108,900 shares. Currently, 5.4% of the company’s shares are sold short. Based on an average trading volume of 61,900 shares, the days-to-cover ratio is presently 4.5 days.
Wall Street Analyst Weigh In
Separately, StockNews.com began coverage on shares of Lipocine in a research note on Friday, April 19th. They set a “sell” rating on the stock.
Read Our Latest Analysis on LPCN
Lipocine Price Performance
Lipocine (NASDAQ:LPCN – Get Free Report) last released its earnings results on Thursday, March 7th. The specialty pharmaceutical company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.11. The firm had revenue of $0.22 million for the quarter. As a group, equities research analysts predict that Lipocine will post -1.49 earnings per share for the current fiscal year.
Lipocine Company Profile
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Featured Stories
- Five stocks we like better than Lipocine
- Basic Materials Stocks Investing
- 3 Stocks Leading the U.S. Agriculture Comeback
- What Does a Stock Split Mean?
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Stock Market Upgrades: What Are They?
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.